BAT2206 is Bio-Thera Solutions’ third EC approvedproduct Guangzhou, China– August , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announcedthat the EC has approved BAT2206 (ustekinum...
DetailsGUANGZHOU, China - Bio-Thera Solutions, a commercial-stage biopharmaceutical companydeveloping innovative therapies and biosimilars today announced an expansion oftheir partnership with SteinCares today with the addition of a third biosimilarto the partnership. Under the agreement,SteinCares will ha...
Guangzhou, China/Budapest, Hungary– # October 9,2024 – Bio-Thera Solutions (688177:SH; “Bio-Thera”), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies andbiosimilars, and Gedeon Richter (“Richter”) announce today they have reached anexclusive comme...
Comparable clinical efficacy and safety in Treatment Period 2 (TP2, Week 24-48) is maintained after switch from reference tocilizumab to TOFIDENCE (BAT1806/BIIB800) Phase 3 clinical data in totality demonstrates biosimilarity between TOFIDENCE (BAT1806/BIIB800) and reference tocilizumab before and a...